Share on StockTwits
 

Equities researchers at JMP Securities set a $191.00 price target on shares of Pharmacyclics (NASDAQ:PCYC) stock in a research report issued on Friday, StockRatingsNetwork.com reports. JMP Securities’ price target would suggest a potential upside of 33.87% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. Analysts at Nomura raised their price target on shares of Pharmacyclics to $166.00 in a research note on Friday. Separately, analysts at Robert W. Baird raised their price target on shares of Pharmacyclics from $163.00 to $173.00 in a research note on Friday. Finally, analysts at Roth Capital raised their price target on shares of Pharmacyclics to $166.00 in a research note on Thursday, February 13th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $152.44.

Pharmacyclics (NASDAQ:PCYC) traded up 6.53% on Friday, hitting $152.002. The stock had a trading volume of 1,924,859 shares. Pharmacyclics has a 52 week low of $71.85 and a 52 week high of $145.30. The stock’s 50-day moving average is $131.5 and its 200-day moving average is $122.5. The company has a market cap of $11.204 billion and a P/E ratio of 56.75.

Pharmacyclics (NASDAQ:PCYC) last issued its quarterly earnings data on Thursday, February 20th. The company reported $0.95 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.67 by $0.28. The company had revenue of $123.60 million for the quarter, compared to the consensus estimate of $85.69 million. On average, analysts predict that Pharmacyclics will post $0.37 earnings per share for the current fiscal year.

Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.